This study is currently not recruiting participants.

A phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of gantenerumab in patients with mild Alzheimer?s disease

Investigating the Effects of an Investigational Medication on Alzheimer's Disease

Not Recruiting
50 years - 90 years
All
Phase N/A

Brief description of study.

In this study, we are hoping to learn about the effects, good or bad, of ?gantenerumab? compared with a ?dummy? drug (also called placebo).

Detailed description of study

In this study, we are hoping to learn about the effects, good or bad, of ?gantenerumab? compared with a ?dummy? drug (also called placebo).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Alzheimer's Disease
  • Age: 50 years - 90 years
  • Gender: All

The purpose of this study is to investigate the effects of an investigational medication compared to a placebo in individuals with Alzheimer's disease. Alzheimer's disease is a condition that affects memory and other important mental functions. In this study, a placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.

Participants in the study will receive either the investigational medication or a placebo. The study will monitor the effects, both positive and negative, of the investigational medication compared to the placebo. This comparison will help understand how the investigational medication might affect Alzheimer's disease symptoms.

  • Who can participate: Participants must be aged 50 to 85 and have a diagnosis of mild to moderate Alzheimer's disease. Other key eligibility factors include stable health conditions and not currently participating in another clinical trial.
  • Study details: Participants will be assigned to receive either the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1402739624

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team